The EU Commission waives commitments regarding the merger between two pharmaceutical companies (Takeda / Shire)

Drakakakis, Stamatis; Papaefthymiou, Argyris; Gavriilidou, Ellie

Article précédent The Italian Supreme Court reinstates remedies imposed by the Italian Competition Authority to mitigate the effects of the acquisition of certain assets of the digital terrestrial Pay-TV (Sky / R2) Article suivant The EU Commission waives all structural remedies committed to by merging pharmaceutical parties due to new significant permanent changes in market conditions during the divestiture process (Takeda / Shire)

28 May 2020

The EU Commission waives commitments regarding the merger between two pharmaceutical companies (Takeda / Shire)

KEYWORDS

Reference

EU Commission, Takeda / Shire, Press release, 28 May 2020

On 28 May 2020, the European Commission waived in their entirety the structural remedies that had been submitted by Takeda in 2018 to have its acquisition of Shire greenlit. The

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

Version PDF

Auteurs

Stamatis Drakakakis
Zepos & Yannopoulos (Athens)

Grèce 35 contributions 3606 visites
Argyris Papaefthymiou
Linklaters (London)

Royaume-Uni 34 contributions 3101 visites
Ellie Gavriilidou
Zepos & Yannopoulos (Athens)

Grèce 29 contributions 2428 visites

Citation

Stamatis Drakakakis, Argyris Papaefthymiou, Ellie Gavriilidou, The EU Commission waives commitments regarding the merger between two pharmaceutical companies (Takeda / Shire), 28 mai 2020, e-Competitions May 2020, Art. N° 100422

Visites 119

Tous les numéros

Latest News issue
Tous les News issues
Latest Special issue
Tous les Special issues